Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows provided by operating activities:
Net (loss) income	$ (74)	$ 2,344
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	267	247
Amortization of operating lease right-of-use assets	588	374
Stock based compensation	240	290
Change in deferred tax assets	42	(402)
Realized loss on sale of investment in iBio Stock	35	0
Unrealized (gain) loss on investment in iBio Stock	(27)	48
Other, net	9	(4)
Changes in operating assets and liabilities:
Accounts receivable, net	205	(394)
Inventories	1,118	(1,401)
Other assets	(39)	(239)
Accounts payable	346	1,285
Accrued expenses and other liabilities	296	(385)
Operating lease obligations	(588)	(375)
Net cash provided by operating activities	2,418	1,388
Cash flows from investing activities:
Purchase of property and equipment	(98)	(451)
Proceeds from sale of iBio Stock	4	0
Proceeds from sale of machinery and equipment	0	21
Net cash used in investing activities	(94)	(430)
Cash flows from financing activities:
Proceeds from exercise of employee stock options	0	7
Repayments (advances) under revolving credit facility	(101)	555
Repayments under term note payables	0	(1,466)
Repayments under finance lease obligations	(25)	0
Net cash used in financing activities	(126)	(904)
Net increase in cash	2,198	54
Cash at beginning of period	331	210
Cash at end of period	2,529	264
Interest paid	31	90
Income taxes paid	0	446
Supplemental disclosures of non-cash flow transactions:
Acquisition of right-of-use assets, net	1,560	0
Amount owed on purchase of property and equipment	$ 0	$ 84